

Provider Network News

Texas to Participate in CMS Cell & Gene Therapy Access Model: Sickle Cell Disease, Beginning Sept. 1

This notice is to inform you of coverage guidance related to gene therapies for the treatment of Sickle Cell Disease (SCD), in alignment with Texas Medicaid policy.

The following gene therapy treatments are now covered for eligible clients:

- **Casgevy** (procedure code J3392)
Indicated for clients 12 years and older with Sickle Cell Disease who experience recurrent vaso-occlusive crises or have transfusion-dependent beta thalassemia.
- **Lyfgenia** (procedure code J3394)
Indicated for clients 12 years of age or older with Sickle Cell Disease and a history of vaso-occlusive events.

These therapies must be administered at Qualified Treatment Centers (QTCs) for members who meet prior authorization criteria.

Guidelines

Parkland Community Health Plan follows the coverage criteria outlined in the Texas Medicaid Provider Procedures Manual (TMPPM). Providers are encouraged to review the relevant guidance and ensure compliance with documentation and authorization requirements.

You can access the TMPPM at the following link <https://www.tmhp.com/resources/provider-manuals/tmppm>.

Parkland Community Health Plan follows the coverage criteria outlined in the Texas Medicaid Provider Procedures Manual (TMPPM), Outpatient Drug Services Handbook, Section 6.112.

If you have questions regarding coverage or prior authorization requirements, please contact PCHP at PCHP.ProviderRelations@phhs.org.